標(biāo)題: Titlebook: Gene Therapy for Cancer; Kelly K. Hunt,Stephan A. Vorburger,Stephen G. Swis Book 2007 Humana Press 2007 angiogenesis.apoptosis.cancer trea [打印本頁] 作者: 拼圖游戲 時(shí)間: 2025-3-21 17:23
書目名稱Gene Therapy for Cancer影響因子(影響力)
書目名稱Gene Therapy for Cancer影響因子(影響力)學(xué)科排名
書目名稱Gene Therapy for Cancer網(wǎng)絡(luò)公開度
書目名稱Gene Therapy for Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Gene Therapy for Cancer被引頻次
書目名稱Gene Therapy for Cancer被引頻次學(xué)科排名
書目名稱Gene Therapy for Cancer年度引用
書目名稱Gene Therapy for Cancer年度引用學(xué)科排名
書目名稱Gene Therapy for Cancer讀者反饋
書目名稱Gene Therapy for Cancer讀者反饋學(xué)科排名
作者: 有偏見 時(shí)間: 2025-3-21 23:01
Rigid bodies and non-inertial frames,from low-level Ad receptor expression and/or anatomical barriers, including extracellular matrix surrounding tumors, have established a great need for research to further improve existing Ad vectors and unravel their true therapeutic potential as anticancer agents. This chapter reviews and discusses作者: Commonwealth 時(shí)間: 2025-3-22 01:18 作者: crucial 時(shí)間: 2025-3-22 08:14 作者: gastritis 時(shí)間: 2025-3-22 12:46 作者: Custodian 時(shí)間: 2025-3-22 16:46
Classical Systems in Quantum Mechanicsc gene products have been evaluated as tools for amplifying or enriching gene-modified HSCs in vivo. These include the homeobox transcription factors, selective amplifier genes, and drug resistance genes. The ability to enrich and repopulate the hematopoietic compartment with therapeutic gene-correc作者: Custodian 時(shí)間: 2025-3-22 19:16 作者: 含水層 時(shí)間: 2025-3-22 23:59 作者: 陰郁 時(shí)間: 2025-3-23 04:51 作者: Banister 時(shí)間: 2025-3-23 06:27
Combination of Gene Therapy with Radiationrated significant potential for the combination of cancer gene therapy with radiotherapy that could lead to improved treatment responses. This chapter attempts to highlight some of the gene therapy approaches that have shown success both in preclinical models and in clinical trials when used in comb作者: 文件夾 時(shí)間: 2025-3-23 11:57
Gene Transfer for Chemoprotection and Enrichment of Hematopoietic Stem Cellsc gene products have been evaluated as tools for amplifying or enriching gene-modified HSCs in vivo. These include the homeobox transcription factors, selective amplifier genes, and drug resistance genes. The ability to enrich and repopulate the hematopoietic compartment with therapeutic gene-correc作者: Lucubrate 時(shí)間: 2025-3-23 17:53 作者: Amnesty 時(shí)間: 2025-3-23 21:43 作者: 沉著 時(shí)間: 2025-3-24 00:35
https://doi.org/10.1007/978-1-59745-222-9angiogenesis; apoptosis; cancer treatment; clinical trial; gene therapy; gene transfer; hematopoietic stem作者: 上下倒置 時(shí)間: 2025-3-24 02:55 作者: miniature 時(shí)間: 2025-3-24 09:44
Nonviral Vector SystemsGene therapy requires efficient vectors for delivering therapeutic genes. Advances in developments of nonviral vectors have been established for improving the efficiency of gene delivery. This chapter describes different nonviral methods as well as their applications. Some new directions in developing nonviral vectors are also discussed.作者: absorbed 時(shí)間: 2025-3-24 12:00
The Cooke triplet optimizations, at increasing the effectiveness of genetic vaccine formulations. Particular emphasis is placed on in vivo nonviral delivery technologies and modifications to safely achieve optimal antigen expression. We will also discuss implications for the future of genetic vaccines.作者: Orgasm 時(shí)間: 2025-3-24 18:20 作者: 拖債 時(shí)間: 2025-3-24 21:51
https://doi.org/10.1007/978-1-4612-0681-1ly, the use of conditional replicating or oncolytic adenovectors in cancer gene therapy or virotherapy has received much attention. Clinical trials with E1-deleted adenovectors and oncolytic adenovirus have shown that adenovector-mediated cancer gene therapy is well tolerated and can produce clinica作者: prosthesis 時(shí)間: 2025-3-25 02:45
Rigid bodies and non-inertial frames, Many of these trials utilize Ad vectors as novel anticancer therapeutics. In recent years, however, initial enthusiasm and high expectations for successful clinical application of Ad-based vectors as efficient anticancer therapeutics has been dampened based on the data obtained during a series of c作者: Ballad 時(shí)間: 2025-3-25 07:02
https://doi.org/10.1007/978-3-540-73616-5als for cancer to date. In an ex vivo setting, conventional replication-defective oncoretrovirus vectors can reliably and efficiently achieve permanent gene transfer which is selective for dividing cells; however, successful application of these vectors in vivo has been difficult because of their re作者: ALOFT 時(shí)間: 2025-3-25 07:28 作者: 補(bǔ)充 時(shí)間: 2025-3-25 13:50
https://doi.org/10.1007/978-94-010-9169-5led to identify a suitable virus, which though unable to cause disease, retained the capability to replicate in cancer cells. In principal, the productive growth of the virus would kill or lyse malignant cells and the newly minted viral progeny would spread the infection, resulting ultimately in the作者: 帶傷害 時(shí)間: 2025-3-25 19:12
Properties of Canonical Transformations,0s that a resurrection of the interest in the ability of certain viruses to preferentially replicate in malignant cells and less so in normal cells occurred, the curiosity being to evaluate whether these agents could be useful in cancer therapy regimes. It was following these reports, demonstrating 作者: Hemodialysis 時(shí)間: 2025-3-25 23:28
https://doi.org/10.1007/978-1-4612-4236-9tial application of parvovirus-based vectors in cancer gene therapy. Unique characteristics of paroviruses such as nonpathogenicity, antioncogenicity, and methods of efficient recombinant vector production have drawn more attention toward utilizing parvovirus-based vectors in cancer gene therapy. Al作者: innate 時(shí)間: 2025-3-26 00:42 作者: transdermal 時(shí)間: 2025-3-26 07:17 作者: 演繹 時(shí)間: 2025-3-26 11:12
Current, Resistance and Circuits, the target cancer cells and high transduction of nontarget normal organs. To address these issues, we have been working on “retargeting” of Ad vectors via transductional or transcriptional targeting. Transductional targeting has been achieved with application of various bridging moieties, genetical作者: 討厭 時(shí)間: 2025-3-26 16:09
Lefteris Tsoulfidis,Persefoni Tsalikiin molecular biology that have allowed relatively easy manipulation of the viral genome, a number of different viruses have been evaluated and shown to have promise as anticancer agents. Of these, herpes simplex virus (HSV) has been perhaps the most intensively investigated. Several strains of repli作者: 治愈 時(shí)間: 2025-3-26 16:53
Mathematical Functions and Techniquesficacy. It focuses on two approaches for delivery of cytokine genes to achieve effective therapy; . delivery using adenoviral vectors also termed “active vaccination,” and cell based approaches using specific immune cells modified with cytokine genes. These approaches have potential advantages for p作者: 不透氣 時(shí)間: 2025-3-26 21:48
Core of a Sequence and the Matrix Class ,,arious genes and several clinical trials for cancer gene therapy have been carried out demonstrating that gene therapy is well tolerated. However, in most cases the efficacy of gene transfer has been very limited. As an alternative, multimodality therapies are being developed with the idea of increa作者: 使混合 時(shí)間: 2025-3-27 04:48 作者: 生氣地 時(shí)間: 2025-3-27 08:08
The Cooke triplet optimizations, at increasing the effectiveness of genetic vaccine formulations. Particular emphasis is placed on in vivo nonviral delivery technologies and modifications to safely achieve optimal antigen expression. We will also discuss implications for the future of genetic vaccines.作者: VAN 時(shí)間: 2025-3-27 11:40 作者: 外來 時(shí)間: 2025-3-27 15:44
Cytokine Gene Therapy for Genitourinary Cancerive vaccination,” and cell based approaches using specific immune cells modified with cytokine genes. These approaches have potential advantages for prostate cancer therapy and possibly other genitourinary malignancies.作者: 我還要背著他 時(shí)間: 2025-3-27 19:47 作者: 包庇 時(shí)間: 2025-3-28 00:07 作者: 煞費(fèi)苦心 時(shí)間: 2025-3-28 03:46 作者: Ambiguous 時(shí)間: 2025-3-28 09:53 作者: 莊嚴(yán) 時(shí)間: 2025-3-28 13:56 作者: 領(lǐng)導(dǎo)權(quán) 時(shí)間: 2025-3-28 16:39
Vesicular Stomatitis Virus and RNA Viruses as Gene Therapy Vectorsthe use of RNA viruses as oncolytic agents in the treatment of malignant disease, focusing on the negative-stranded RNA virus, VSV. The general mechanisms by which oncolytic viruses such as VSV achieve their antitumor effectiveness and specificity are discussed, including the role of the innate immune system involving the interferon response.作者: 欺騙世家 時(shí)間: 2025-3-28 22:00 作者: 勉強(qiáng) 時(shí)間: 2025-3-29 00:43 作者: Metamorphosis 時(shí)間: 2025-3-29 04:17 作者: Intact 時(shí)間: 2025-3-29 09:19 作者: 壓碎 時(shí)間: 2025-3-29 14:16
Gene Silencing Therapy Against Cancerloped into therapeutics for cancer by selectively silencing aberrantly activated oncogenes. However, major challenges of delivery, specificity and efficacy need to be overcome before siRNAs can be used as therapeutic agents.作者: 松雞 時(shí)間: 2025-3-29 16:27
Oncolytic Herpes Simplex for Gene Therapy in Preclinical and Clinical Trialsting the viral genome to more specifically target tumor cells, to further enhance efficacy while maintaining safety, and to assess the role of oncolytic HSV in combination with chemotherapy and radiation therapy.作者: KIN 時(shí)間: 2025-3-29 20:08 作者: 知識分子 時(shí)間: 2025-3-30 00:34
Monica S. Cyrino,Meredith E. Safranes. Both preclinical and clinical studies have indicated that restoring the normal function of these genes may be an effective means of cancer therapy although full realization of any anticancer benefit will depend on effective delivery of these genes to cancer cells.作者: 藝術(shù) 時(shí)間: 2025-3-30 04:30 作者: 過渡時(shí)期 時(shí)間: 2025-3-30 11:51
Oncogenes, Tumor Suppressor Genes and Apoptosis-Inducing Genes Utilized in Cancer Gene Therapyes. Both preclinical and clinical studies have indicated that restoring the normal function of these genes may be an effective means of cancer therapy although full realization of any anticancer benefit will depend on effective delivery of these genes to cancer cells.作者: BARB 時(shí)間: 2025-3-30 14:19
Book 2007interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowin作者: originality 時(shí)間: 2025-3-30 16:53 作者: Hypopnea 時(shí)間: 2025-3-31 00:27 作者: backdrop 時(shí)間: 2025-3-31 03:40
